Statin Discontinuation in Advanced Illness

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

381 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-03

Study Completion Date

2013-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if there is a difference in survival rate at 60 days after enrollment between patients with advanced life-limiting illness for whom statins are discontinued vs. for patients with advanced life-limiting illness who are maintained on the medication. Secondary outcomes of this study will determine the effects of medication cessation on overall survival, important cardiovascular events, quality of life (QOL), symptoms, performance status, polypharmacy issues, satisfaction with care, and costs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Statins In The Elderly

NCT02547883

Mortality

COMPLETED NA

STREAM Trial - Statins in Multimorbid Older Adults Without Cardiovascular Disease

NCT05178420

Statin Treatment for Primary Prevention

ACTIVE_NOT_RECRUITING NA

Effect of Simvastatin Withdrawal on Ocular Endothelial Function

NCT02533141

Healthy

WITHDRAWN PHASE4

STREAM Trial - Subclinical Atherosclerosis

NCT05482399

Statin Treatment for Primary Prevention

RECRUITING NA

The Impact of Statin Holiday in Dialysis Patients Over 70 Years Old on Mental Function, Physical Function and Frailty

NCT03663049

ESRD Cardiovascular Diseases

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, over 80% of the population is expected to die of chronic life-limiting illnesses, predominant among which are the various manifestations of cardiovascular disease, cancer, dementia, and chronic lung disease. Patients with high cholesterol and those potentially at risk for atherosclerotic heart disease and stroke are often treated preventively with HMG Co-A reductase inhibitors (a.k.a., statins). Clinical trial evidence supports the use of statins for patients with hyperlipidemia and established ischemic heart disease to reduce risk of future cardiovascular events and mortality, and to reduce risk of future cardiovascular events in patients with multiple cardiac risk factors. Beneficial outcomes are evident in these trials after 3-6 years of treatment. Hence, statins are among the most prescribed medications in the world. In the United States, over 25% of Medicare beneficiaries take a statin medication. Statin medications are frequently continued until the patient can no longer eat or swallow at the end of life, because there are no evidence-based guidelines regarding when or how to discontinue medications for co-morbidities. The risks and costs vs. benefits of statins for palliative care patients, for whom prognosis is limited, remains a genuine clinical uncertainty. Meanwhile, medications for symptoms and other concerns accumulate as illness progresses, and therefore polypharmacy and compounding medication side effects are troublesome problems in the setting of advanced life-limiting illness. While multiple studies have demonstrated the benefit of long-term preventive statin use for patients at cardiovascular risk, other studies have supported the discontinuation of medications (specifically statins) in end-stage disease. A rational approach to medication discontinuation, specifically statin discontinuation, therefore has the potential to reduce patient burden, polypharmacy, and side effects, while also preserving healthcare resources for more beneficial interventions.

This study is a multi-site randomized controlled trial of discontinuing vs. continuing statin medications in patients with advanced life-limiting illness. Eligible participants are adults with advanced life-limiting illness with an estimated prognosis of 1-6 months who are on statins for primary or secondary prevention of cardiovascular events. The primary outcome is survival rate at 60 days; secondary outcomes address cardiovascular events, polypharmacy, medication adverse effects, quality of life (QOL), and measures of the patient's health-related experience. The primary hypothesis is that discontinuing statins will not influence survival. Secondary hypotheses are that discontinuation of statins will not adversely affect cardiovascular events or overall QOL, but will improve statin-related symptoms and decrease polypharmacy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Palliative Medicine Cardiovascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Continue Statins

Participant will continue on statins as per usual

Group Type NO_INTERVENTION

No interventions assigned to this group

Discontinue statins

Participant will stop taking their statin drugs

Group Type EXPERIMENTAL

discontinue statins

Intervention Type OTHER

patients will be randomized to either continue taking statins or discontinue.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

discontinue statins

patients will be randomized to either continue taking statins or discontinue.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \>18 years old;
* have an advanced life-limiting illness;
* have a life expectancy of \>1 month, AND patient exhibits declining functional status, defined as a reduction in Australia-modified Karnofsky Performance Status (AKPS)22 score to \<80% in the previous 3 months;
* be on a statin medication for primary or secondary prevention of cardiovascular disease for ≥3 months;
* have adequately intact cognitive status to provide informed consent and complete the baseline assessment, as evidenced by a Short Portable Mental Status Questionnaire (SPMSQ)23 score of ≥6;
* provide informed consent; and,
* speak and read English at or above a grade 5 level (per patient or caregiver report).

Exclusion Criteria

* primary treating physician/care provider estimates their life expectancy as \< 1 month;
* under the care of a primary treating physician/primary care provider who is unwilling to have the patient enrolled;
* not consenting;
* having known active cardiovascular disease or sufficient risk of active cardiovascular disease to require ongoing therapy with statin drugs, in the opinion of the treating physician; OR,
* exhibiting obvious symptoms of myositis, known liver function test (LFT) abnormalities of \>2.5x the upper limit of normal (ULN), known creatine kinase (CK) abnormalities of \>2.5x ULN, or other contraindications to continuing statins, in the opinion of the treating physician.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No